This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Apellis Pharmaceuticals（APLS）株式概要
アペリス・ファーマシューティカルズ社は、商業段階のバイオ医薬品会社で、アンメットニーズの高い疾病を治療するための新規治療化合物の発見、開発、商業化に注力している。 詳細
APLS Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Apellis Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$41.03 |
| 52週高値 | US$41.14 |
| 52週安値 | US$16.61 |
| ベータ | -0.25 |
| 1ヶ月の変化 | 0.39% |
| 3ヶ月変化 | 89.08% |
| 1年変化 | 135.13% |
| 3年間の変化 | -53.83% |
| 5年間の変化 | -14.22% |
| IPOからの変化 | 192.44% |
最新ニュース
Recent updates
ナラティブの更新 • Apr 29
APLS: Biogen Deal Terms And Mixed Ratings Will Guide Future Repricing
Analysts have raised the fair value estimate for Apellis Pharmaceuticals to about $40.93, citing Street research that combines several recent price target increases with a series of downgrades following Biogen's acquisition announcement, along with updated views on long-term P/E assumptions and risk. Analyst Commentary Street research around the Biogen acquisition announcement shows a split in how analysts are framing Apellis Pharmaceuticals, with some highlighting upside to long-term value and others focusing on execution and pricing risks.ナラティブの更新 • Apr 15
APLS: Balanced Biogen Deal And Mixed Ratings Will Shape Future Repricing
Apellis Pharmaceuticals' updated fair value estimate has shifted from $35.71 to $39.93 per share as analysts factor in higher long run P/E assumptions near 42x, alongside recent price target changes that include several upgrades, downgrades and target raises from firms such as Mizuho, JPMorgan, Morgan Stanley and RBC Capital. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split tape, with several firms lifting price targets while a cluster of downgrades points to fresh execution and valuation questions.ナラティブの更新 • Apr 01
APLS: Syfovre Outlook And Downgrade Wave Will Limit Future Repricing
Analysts now see fair value for Apellis Pharmaceuticals at about $35.71 per share, up from roughly $33.60, reflecting updated views on revenue growth, margins, discount rates, and a somewhat higher future P/E multiple after a mix of recent price target raises, initiations, and downgrades across the Street. Analyst Commentary Street research on Apellis Pharmaceuticals reflects a mixed but engaged view, with both bullish and bearish analysts adjusting targets, ratings, and coverage in response to recent reports and product updates.Seeking Alpha • Mar 31
Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing
Summary Biogen acquires Apellis for $41/share, a 140% premium, aiming to leverage Apellis’ nephrology sales force and product portfolio. Syfovre’s safety issues have stabilized, but its commercial prospects remain limited versus Astellas’ Izervay, justifying Biogen’s cautious CVR structure. Biogen’s acquisition thesis hinges on felzartamab’s potential in complement-mediated rare diseases, especially AMR, targeting $800M+ peak sales. I downgrade APLS to 'Sell' post-acquisition, as upside is realized; BIIB remains a 'Hold' given execution risk and dependence on felzartamab’s success. Read the full article on Seeking Alphaナラティブの更新 • Mar 18
APLS: Kidney Disease Launch And Index Adds Will Drive Future Repricing
Narrative Update on Apellis Pharmaceuticals The updated analyst price target framework now aligns with Street research that has recently adjusted Apellis price objectives in a roughly $18 to $44 range, with analysts pointing to demand trends for Syfovre and Empaveli, mixed views on growth beyond the current Q4 reporting period, and differing assumptions for revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Apellis Pharmaceuticals presents a mixed picture, with price targets spanning roughly US$18 to US$44 and a range of views on execution, product demand and future growth.
ナラティブの更新 • Mar 04
APLS: Future C3G Launch Execution Will Drive Bullish Re Rating Potential
Apellis Pharmaceuticals' updated analyst price targets cluster around the high teens to mid $40s, with modest adjustments up and down as analysts factor in the Q4 update, expectations for flat Syfovre pricing into FY26, progress in the C3G launch, and slightly revised assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Apellis Pharmaceuticals reflects a mixed but generally constructive stance, with price targets spanning from the high teens into the mid $40s and a blend of Neutral, Buy, and Overweight views.ナラティブの更新 • Feb 17
APLS: Kidney Disease Launch And Index Adds Will Support Future Repricing
Analysts have nudged their consolidated price target and fair value framework for Apellis slightly higher to $33.95, reflecting a blend of cautious optimism from fresh Neutral initiations and upgrades, along with mixed target revisions following the recent Q4 pre-announcement and C3G launch commentary. Analyst Commentary Recent research has focused on how Apellis is executing around its Q4 pre announcement and the early C3G launch, and what that means for valuation and risk.ナラティブの更新 • Feb 03
APLS: Kidney Disease Launch And Index Additions Will Support Future Share Recovery
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about US$1.44 per share, reflecting more cautious assumptions on revenue growth and profit margins, even as some recent research updates point to steady product launches and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split view, with some analysts focusing on product execution and others emphasizing revenue uncertainty and guidance gaps.ナラティブの更新 • Jan 20
APLS: Future C3G Renal Uptake Will Drive Bullish Re Rating Potential
Analysts have slightly increased their overall price expectations for Apellis, with recent Street targets clustering in a US$27 to US$45 range, as they balance cautious views on Syfovre revenue trends and guidance gaps against ongoing uptake in C3G and related renal indications. Analyst Commentary Recent Street research shows a mix of caution and optimism on Apellis, with several bullish analysts highlighting areas where they see the story improving around execution, revenue mix and potential upside to current expectations.ナラティブの更新 • Jan 05
APLS: Future Renal Indication Execution Will Drive Bullish Re Rating Potential
Analysts have trimmed their price targets for Apellis Pharmaceuticals, with recent cuts to US$45 and US$27. These moves reflect concerns about "flattish" Syfovre revenue and uncertainty around Empaveli's early renal indications, even as long term fair value assumptions and projected revenue growth in some models remain unchanged.ナラティブの更新 • Dec 14
APLS: Future Kidney Indication Uptake Will Drive Bullish Re-Rating Potential
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about $5 per share. They cite higher perceived risk, slower expected revenue growth from Syfovre and Empaveli, and somewhat lower long term margin assumptions, although several covering firms remain generally supportive.ナラティブの更新 • Nov 29
APLS: Kidney Disease Indication Launch Will Drive Share Price Recovery Ahead
Analysts have modestly lowered their average price target for Apellis Pharmaceuticals. They cite cautious outlooks on revenue growth and recent segment performance, with new targets ranging from $27 to $45 per share compared to prior targets up to $52.ナラティブの更新 • Nov 15
APLS: Future Revenue From Kidney Disease Expansion Will Drive Shares Higher
Analysts have modestly lowered their fair value estimate for Apellis Pharmaceuticals from approximately $36.50 to $35.39 per share. This adjustment is due to concerns over slower revenue growth and contracting profit margins following recent company updates.ナラティブの更新 • Oct 31
APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside
Analysts have lowered their average price target for Apellis Pharmaceuticals, reducing it by nearly $1 to $36.50. This adjustment reflects moderating revenue growth forecasts and a higher discount rate, although expectations for profit margin have marginally improved.ナラティブの更新 • Sep 27
FDA Label Expansion And SYFOVRE Will Unlock Future Value
Analyst price targets for Apellis Pharmaceuticals have edged lower to $37.47 as positive signals from Syfovre sales and pipeline opportunities are tempered by concerns over limited revenue guidance and commercial ramp uncertainties. Analyst Commentary Bullish analysts cite stabilization in the Geographic Atrophy (GA) market and optimism around the ongoing launches in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).ナラティブの更新 • Aug 27
FDA Label Expansion And SYFOVRE Will Unlock Future Value
The consensus analyst price target for Apellis Pharmaceuticals has risen modestly to $38.56, reflecting improving sentiment from stabilizing Geographic Atrophy market dynamics, continued Syfovre injection growth, and upside potential from Empaveli expansions, despite some concerns over Syfovre sales guidance and a possibly slower Empaveli ramp. Analyst Commentary Bullish analysts point to stabilizing Geographic Atrophy market dynamics and the ongoing launch initiatives in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) as a driver for upward price revisions.分析記事 • Jul 29
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • May 02
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.Seeking Alpha • Mar 05
Apellis Pharmaceuticals: A Mixed Bag
Summary Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand. The analyst firm community is quite mixed on the current prospects around Apellis Pharmaceuticals, however. An analysis around APLS stock follows in the paragraphs below. Read the full article on Seeking Alpha株主還元
| APLS | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0% | 3.1% | 1.2% |
| 1Y | 135.1% | 34.6% | 28.7% |
業界別リターン: APLS過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: APLS過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。
価格変動
| APLS volatility | |
|---|---|
| APLS Average Weekly Movement | 39.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: APLSの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: APLSの 週次ボラティリティ は、過去 1 年間で21%から39%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2009 | 736 | Cedric Francois | apellis.com |
アペリス・ファーマシューティカルズ・インクは、商業段階のバイオ医薬品企業であり、アンメットニーズの高い疾患に対する新規治療化合物の発見、開発、商業化に注力している。同社は、発作性夜間ヘモグロビン尿症治療薬EMPAVELI、加齢黄斑変性および地理的萎縮症（GA）二次性萎縮症治療薬SYFOVREを提供しています。また、C3糸球体症および免疫複合体膜増殖性糸球体腎炎、巣状分節性糸球体硬化症、移植片機能遅延を治療するEMPAVELI、GAを治療する低分子干渉RNA（siRNA）であるAPL-3007も開発している。さらに、新生児Fc受容体（FcRn）を標的とする治療薬APL-9099の前臨床試験を実施しており、1回投与で将来の標的適応症に対するファースト・イン・クラスの遺伝子編集治療薬となる可能性がある。また、スウェーデンのオーファン・バイオビトラム社（publ）とペグセタコプラン（pegcetacoplan）の開発および商業化に関する提携およびライセンス契約を締結しているほか、ビーム・セラピューティクス社（Beam Therapeutics, Inc.）とは、補体駆動性疾患に対する新たな治療法を発見するためのビームの塩基編集技術の利用に焦点を当てた提携を行っている。アペリス・ファーマシューティカルズ・インクは2009年に設立され、マサチューセッツ州ウォルサムに本社を置いている。2026年5月14日現在、アペリス・ファーマシューティカルズ・インクはバイオジェン・インクの子会社として活動している。
Apellis Pharmaceuticals, Inc. 基礎のまとめ
| APLS 基礎統計学 | |
|---|---|
| 時価総額 | US$5.25b |
| 収益（TTM） | US$133.27m |
| 売上高(TTM) | US$1.11b |
39.4x
PER（株価収益率4.8x
P/SレシオAPLS は割高か？
公正価値と評価分析を参照収益と収入
| APLS 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.11b |
| 売上原価 | US$394.82m |
| 売上総利益 | US$710.47m |
| その他の費用 | US$577.20m |
| 収益 | US$133.27m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 1.04 |
| グロス・マージン | 64.28% |
| 純利益率 | 12.06% |
| 有利子負債／自己資本比率 | 109.9% |
APLS の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/16 19:31 |
| 終値 | 2026/05/13 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Apellis Pharmaceuticals, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28
| アナリスト | 機関 |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Eliana Merle | Barclays |